After 2006, patients with ER-negative/HER2-positive breast cancer were treated with trastuzumab and, in these patients, membranous expression of PRPF38B in the primary cancer was significantly associated with better disease-free survival (DFS) at the 5 year follow-up. This evidence concerns the gene ERBB2 and breast cancer.